Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to keep advanced lung cancer at bay

NCT ID NCT03519971

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This large, late-stage trial is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation works better for people with a specific type of advanced lung cancer that cannot be surgically removed. The study involves 328 patients worldwide and compares the new combination against the standard treatment plus a placebo. The main goal is to see if the new approach helps control the cancer for a longer period without it getting worse.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Barretos, 14784-400, Brazil

  • Research Site

    Curitiba, 81520-060, Brazil

  • Research Site

    Florianópolis, 88034-000, Brazil

  • Research Site

    Fortaleza, 60336-045, Brazil

  • Research Site

    Porto Alegre, 90035-003, Brazil

  • Research Site

    Porto Alegre, 90610-000, Brazil

  • Research Site

    Porto Alegre, 91350-200, Brazil

  • Research Site

    Ribeirão Preto, 14021-636, Brazil

  • Research Site

    Ribeirão Preto, 14048900, Brazil

  • Research Site

    São José do Rio Preto, 15090-000, Brazil

  • Research Site

    São Paulo, 01246-000, Brazil

  • Research Site

    Brno, 656 53, Czechia

  • Research Site

    Ostrava, 703 00, Czechia

  • Research Site

    Prague, 128 08, Czechia

  • Research Site

    Budapest, 1083, Hungary

  • Research Site

    Budapest, 1121, Hungary

  • Research Site

    Győr, 9024, Hungary

  • Research Site

    Gyula, 5700, Hungary

  • Research Site

    Törökbálint, 2045, Hungary

  • Research Site

    Bangalore, 560068, India

  • Research Site

    Chennai, 600035, India

  • Research Site

    Gūrgaon, 122001, India

  • Research Site

    Karamsad, 388325, India

  • Research Site

    Mumbai, 400053, India

  • Research Site

    Nashik, 422005, India

  • Research Site

    New Delhi, 110063, India

  • Research Site

    Vadodara, 390007, India

  • Research Site

    Bunkyō City, 113-8603, Japan

  • Research Site

    Fukuoka, 812-8582, Japan

  • Research Site

    Kōtoku, 135-8550, Japan

  • Research Site

    Kyoto, 606-8507, Japan

  • Research Site

    Nagoya, 464-8681, Japan

  • Research Site

    Sayama, 589-8511, Japan

  • Research Site

    Sendai, 980-0873, Japan

  • Research Site

    Yokohama, 241-8515, Japan

  • Research Site

    Aguascalientes, 20230, Mexico

  • Research Site

    Guadalajara, 44280, Mexico

  • Research Site

    Mexico City, 0 3100, Mexico

  • Research Site

    Mérida, 97134, Mexico

  • Research Site

    México, 04700, Mexico

  • Research Site

    Orizaba, 94300, Mexico

  • Research Site

    La Libertad, 13013, Peru

  • Research Site

    Lima, 15033, Peru

  • Research Site

    Lima, L27, Peru

  • Research Site

    Lima, LIMA 27, Peru

  • Research Site

    Lima, LIMA 34, Peru

  • Research Site

    Lima, LIMA 41, Peru

  • Research Site

    Cebu City, 6000, Philippines

  • Research Site

    City of Taguig, 1634, Philippines

  • Research Site

    Iloilo City, 5000, Philippines

  • Research Site

    Makati, 1229, Philippines

  • Research Site

    Manila, 1015, Philippines

  • Research Site

    Quezon City, Philippines

  • Research Site

    Bydgoszcz, 85-796, Poland

  • Research Site

    Elblag, 02-300, Poland

  • Research Site

    Gdansk, 80-952, Poland

  • Research Site

    Olsztyn, 10-228, Poland

  • Research Site

    Warsaw, 02-781, Poland

  • Research Site

    Arkhangelsk, 163045, Russia

  • Research Site

    Chelyabinsk, 454087, Russia

  • Research Site

    Moscow, 115478, Russia

  • Research Site

    Moscow, 115533, Russia

  • Research Site

    Moscow, 125367, Russia

  • Research Site

    Omsk, 644013, Russia

  • Research Site

    Rostov-on-Don, 344037, Russia

  • Research Site

    Saint Petersburg, 197758, Russia

  • Research Site

    Busan, 48108, South Korea

  • Research Site

    Chungcheongbuk-do, 28644, South Korea

  • Research Site

    Gyeongsangnam-do, 52727, South Korea

  • Research Site

    Seoul, 03080, South Korea

  • Research Site

    Seoul, 05505, South Korea

  • Research Site

    Seoul, 6351, South Korea

  • Research Site

    Bangkok, 10330, Thailand

  • Research Site

    Bangkok, 10400, Thailand

  • Research Site

    Hat Yai, 90110, Thailand

  • Research Site

    Khon Kaen, 40002, Thailand

  • Research Site

    Mueang, 50200, Thailand

  • Research Site

    Ankara, 06230, Turkey (Türkiye)

  • Research Site

    Ankara, Turkey (Türkiye)

  • Research Site

    Antalya, 07059, Turkey (Türkiye)

  • Research Site

    Diyarbakır, 21280, Turkey (Türkiye)

  • Research Site

    Istanbul, 34030, Turkey (Türkiye)

  • Research Site

    Izmir, 35100, Turkey (Türkiye)

  • Research Site

    Hanoi, 100000, Vietnam

  • Research Site

    Hanoi, 10000, Vietnam

  • Research Site

    Ho Chi Minh City, 700000, Vietnam

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER